Compare · AVTR vs BNGO
AVTR vs BNGO
Side-by-side comparison of Avantor Inc. (AVTR) and Bionano Genomics Inc. (BNGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and BNGO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $10.88B, about 674.5x BNGO ($16.1M).
- AVTR has been more active in the news (6 items in the past 4 weeks vs 1 for BNGO).
- AVTR has more recent analyst coverage (25 ratings vs 5 for BNGO).
- Company
- Avantor Inc.
- Bionano Genomics Inc.
- Price
- -
- -
- Market cap
- $10.88B
- $16.1M
- 1M return
- +3.53%
- -
- 1Y return
- +11.03%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Latest AVTR
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
- EVP and CFO Garner Todd W was granted 49,688 shares (SEC Form 4)
- SEC Form 3 filed by new insider Garner Todd W
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor appoints new Chief Financial Officer
- UBS initiated coverage on Avantor with a new price target
- Amendment: Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- President and CEO Ligner Emmanuel covered exercise/tax liability with 29,803 shares, decreasing direct ownership by 4% to 737,334 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.07% to 248,864 units (SEC Form 4) (withholding tax)
Latest BNGO
- Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
- Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Bionano Genomics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
- Interim Chief Executive Luderer Albert bought $4,845 worth of shares (4,000 units at $1.21) (SEC Form 4)
- Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
- Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Interim Chief Executive Luderer Albert bought $4,860 worth of shares (4,000 units at $1.22) (SEC Form 4)
- SEC Form 10-Q filed by Bionano Genomics Inc.
- Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits